A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (c-IBS)

Trial Profile

A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (c-IBS)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2010

At a glance

  • Drugs Renzapride (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Alizyme
  • Most Recent Events

    • 16 Feb 2010 Results published in Alimentary Pharmacology and Therapeutics.
    • 23 Apr 2008 Due to the limited efficacy of renzapride demonstrated in this trial further development of renzapride is being discontinued as reported by Alizyme.
    • 22 Jan 2008 The expected completion date for this trial is now 1 Feb 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top